|
Research and Markets: HIV: Pipelines & Deals 2003
DUBLIN, Ireland, Jul 19, 2004 (BUSINESS WIRE) -- The United Nations Program on
HIV/AIDS and the World Health Organization Concur That While Prevention of HIV
is a Main Focus to Finally Stop the Aids Epidemic, No Approved Prevention
Products Have Reached the Market
Research and Markets (http://www.researchandmarkets.com)
has announced the addition of HIV: Pipelines & Deals 2003 to their offering.
The report provides information on the development activities of over 65
worldwide located both public and (small) private companies in the field of
HIV therapy and prevention.
At the end of November 2003 the joint United Nations Program on HIV/AIDS and
the World Health Organization presented the latest figures on HIV-infection.
Their conclusion was that the global AIDS epidemic still shows no signs of
abating. While prevention of HIV is a main focus to finally stop the AIDS
epidemic, until now no approved prevention products have reached the market.
On the other hand a growing number of HIV therapeutics is since several years
introduced on the market.
Up to 2003 reverse transcriptase inhibitors and protease inhibitors were the
only two product classes available on the market. Early 2003 the first fusion
inhibitor entered the market. Next to these products, a growing number of
drugs are under development for both HIV prevention and therapy.
Categorized according to the various succeeding steps in HIV-infection this
report reviews more than 100 drugs currently under development. Deals closed
in 2003 for these products are highlighted. Company snapshots for over 70
public and private companies are presented. These snapshots include contact
details, venture capital companies involved for private companies c.q. limited
financial information for public companies, HIV research focus, HIV products
in development and HIV strategic alliances with industrial partners.
HIV: Pipelines & Deals 2003 is of potential interest for business development
and investment groups, funding organizations and CROs evaluating opportunities
with regard to strategic alliances, financing and identification of new
clients and/or products.
Report Contents
1. Introduction
2. HIV Products under development
3. Deal activity 2003
Appendices
Appendix 1: Company snapshots
Acceleration biopharmaceuticals, Achillion Pharmaceuticals, Advanced Life
Sciences, Aethlon Medical, AlphaVax, AnorMED, Avant Immunotherapeutics
Aventis Pharma, Axxima Pharmaceuticals, Bavarian Nordic, BioDelivery Sciences,
Biosyn, Biota Holdings, BioVex, Boehringer Ingelheim, Bristol Myers Squibb,
Chiron, CytoDyn, CytRx Corporation, Dimethaid Research, EMD Pharmaceuticals,
Enzo Biochem, Epimmune, FIT Biotech, GeoVax, Gilead Sciences, GlaxoSmithKline,
Hemispherx BioPharma, HIV-VAC, Hollis-Eden Pharmaceuticals, Hybridon, The
Immune Response Corporation, International Therapeutics, Johnson & Johnson,
Lauras, Lipid Sciences, Maxygen, Medarex
Medivir, Merck & Co., ML Laboratories, MolMed, Myriad Genetics, Oxford
BioMedica, Oxxon Pharmaccines, Panacos Pharmaceuticals, Pfizer, Polydex
Pharmaceuticals, The Population Council, Praecis Pharmaceuticals, Procyon
Biopharma, Progenics Pharmaceuticals, PTC Therapeutics, Redox Pharmaceutical
Corporation, Roche, Samaritan Pharmaceuticals, Schering-Plough Corporation
Shire Pharmaceuticals, Tanox, Trimeris, Tripep, United Biomedical, URRMA
Biopharma, VaxGen, Vertex Pharmaceuticals, VGX Pharmaceuticals, Virocell
Viral Genetics, Virax Holdings,VIRxSYS
Appendix 2: Products listed by development status
Appendix 3: Venture capital companies
For more information visit
http://www.researchandmarkets.com/reports/c2873
SOURCE: Research and Markets
Research and Markets
Laura Wood
Senior Manager
Fax : +353 1 4100 980
press@researchandmarkets.com
|
|
